Health and economic burden of antimicrobial-resistant infections in Australian hospitals

A population-based model

Teresa M. Wozniak, Emily J. Bailey, Nicholas Graves

    Research output: Contribution to journalArticleResearchpeer-review

    Abstract

    Objective: To estimate the additional health and economic burden of antimicrobial-resistant (AMR) infections in Australian hospitals.

    Methods: A simulation model based on existing evidence was developed to assess the additional mortality and costs of healthcare-associated AMR Escherichia coli (E. coli), Klebsiella pneumoniae, Pseudomonas aeruginosa, Enterococcus faecium, and Staphylococcus aureus infections.

    Setting: Australian public hospitals.

    Findings: Australian hospitals spent an additional AUD$5.8 million (95% uncertainty interval [UI], $2.2-$11.2 million) per year treating ceftriaxone-resistant E.coli bloodstream infections (BSI), and an estimated AUD$5.5 million per year (95% UI, $339,633-$22.7 million) treating MRSA patients. There are no reliable estimates of excess morbidity and mortality from AMR infections in sites other than the blood and in particular for highly prevalent AMR E. coli causing urinary tract infections (UTIs).

    Conclusion: The limited evidence-base of the health impact of resistant infection in UTIs limits economic studies estimating the overall burden of AMR. Such data are increasingly important and are urgently needed to support local clinical practice as well as national and global efforts to curb the spread of AMR.

    Original languageEnglish
    Pages (from-to)320-327
    Number of pages8
    JournalInfection Control and Hospital Epidemiology
    Volume40
    Issue number3
    DOIs
    Publication statusPublished - Mar 2019

    Fingerprint

    Economics
    Health
    Infection
    Urinary Tract Infections
    Population
    Uncertainty
    Escherichia coli
    Escherichia coli Infections
    Enterococcus faecium
    Ceftriaxone
    Mortality
    Public Hospitals
    Klebsiella pneumoniae
    Methicillin-Resistant Staphylococcus aureus
    Health Care Costs
    Pseudomonas aeruginosa
    Staphylococcus aureus
    Morbidity

    Cite this

    @article{bbed6996ce644605b685b8362c5c2481,
    title = "Health and economic burden of antimicrobial-resistant infections in Australian hospitals: A population-based model",
    abstract = "Objective: To estimate the additional health and economic burden of antimicrobial-resistant (AMR) infections in Australian hospitals.Methods: A simulation model based on existing evidence was developed to assess the additional mortality and costs of healthcare-associated AMR Escherichia coli (E. coli), Klebsiella pneumoniae, Pseudomonas aeruginosa, Enterococcus faecium, and Staphylococcus aureus infections.Setting: Australian public hospitals.Findings: Australian hospitals spent an additional AUD$5.8 million (95{\%} uncertainty interval [UI], $2.2-$11.2 million) per year treating ceftriaxone-resistant E.coli bloodstream infections (BSI), and an estimated AUD$5.5 million per year (95{\%} UI, $339,633-$22.7 million) treating MRSA patients. There are no reliable estimates of excess morbidity and mortality from AMR infections in sites other than the blood and in particular for highly prevalent AMR E. coli causing urinary tract infections (UTIs).Conclusion: The limited evidence-base of the health impact of resistant infection in UTIs limits economic studies estimating the overall burden of AMR. Such data are increasingly important and are urgently needed to support local clinical practice as well as national and global efforts to curb the spread of AMR.",
    author = "Wozniak, {Teresa M.} and Bailey, {Emily J.} and Nicholas Graves",
    year = "2019",
    month = "3",
    doi = "10.1017/ice.2019.2",
    language = "English",
    volume = "40",
    pages = "320--327",
    journal = "Infection Control and Hospital Epidemiology",
    issn = "0899-823X",
    publisher = "Cambridge University Press",
    number = "3",

    }

    Health and economic burden of antimicrobial-resistant infections in Australian hospitals : A population-based model. / Wozniak, Teresa M.; Bailey, Emily J.; Graves, Nicholas.

    In: Infection Control and Hospital Epidemiology, Vol. 40, No. 3, 03.2019, p. 320-327.

    Research output: Contribution to journalArticleResearchpeer-review

    TY - JOUR

    T1 - Health and economic burden of antimicrobial-resistant infections in Australian hospitals

    T2 - A population-based model

    AU - Wozniak, Teresa M.

    AU - Bailey, Emily J.

    AU - Graves, Nicholas

    PY - 2019/3

    Y1 - 2019/3

    N2 - Objective: To estimate the additional health and economic burden of antimicrobial-resistant (AMR) infections in Australian hospitals.Methods: A simulation model based on existing evidence was developed to assess the additional mortality and costs of healthcare-associated AMR Escherichia coli (E. coli), Klebsiella pneumoniae, Pseudomonas aeruginosa, Enterococcus faecium, and Staphylococcus aureus infections.Setting: Australian public hospitals.Findings: Australian hospitals spent an additional AUD$5.8 million (95% uncertainty interval [UI], $2.2-$11.2 million) per year treating ceftriaxone-resistant E.coli bloodstream infections (BSI), and an estimated AUD$5.5 million per year (95% UI, $339,633-$22.7 million) treating MRSA patients. There are no reliable estimates of excess morbidity and mortality from AMR infections in sites other than the blood and in particular for highly prevalent AMR E. coli causing urinary tract infections (UTIs).Conclusion: The limited evidence-base of the health impact of resistant infection in UTIs limits economic studies estimating the overall burden of AMR. Such data are increasingly important and are urgently needed to support local clinical practice as well as national and global efforts to curb the spread of AMR.

    AB - Objective: To estimate the additional health and economic burden of antimicrobial-resistant (AMR) infections in Australian hospitals.Methods: A simulation model based on existing evidence was developed to assess the additional mortality and costs of healthcare-associated AMR Escherichia coli (E. coli), Klebsiella pneumoniae, Pseudomonas aeruginosa, Enterococcus faecium, and Staphylococcus aureus infections.Setting: Australian public hospitals.Findings: Australian hospitals spent an additional AUD$5.8 million (95% uncertainty interval [UI], $2.2-$11.2 million) per year treating ceftriaxone-resistant E.coli bloodstream infections (BSI), and an estimated AUD$5.5 million per year (95% UI, $339,633-$22.7 million) treating MRSA patients. There are no reliable estimates of excess morbidity and mortality from AMR infections in sites other than the blood and in particular for highly prevalent AMR E. coli causing urinary tract infections (UTIs).Conclusion: The limited evidence-base of the health impact of resistant infection in UTIs limits economic studies estimating the overall burden of AMR. Such data are increasingly important and are urgently needed to support local clinical practice as well as national and global efforts to curb the spread of AMR.

    UR - http://www.scopus.com/inward/record.url?scp=85063189934&partnerID=8YFLogxK

    U2 - 10.1017/ice.2019.2

    DO - 10.1017/ice.2019.2

    M3 - Article

    VL - 40

    SP - 320

    EP - 327

    JO - Infection Control and Hospital Epidemiology

    JF - Infection Control and Hospital Epidemiology

    SN - 0899-823X

    IS - 3

    ER -